Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival

Leukemia

Volumn 13, Issue 1, 1999, Pages 44-53

  Gupta, P ^a,b   Niehans, G A ^a   LeRoy, S C ^a   Gupta, K ^a   Morrison, V A ^a   Schultz, C ^a   Knapp, D J ^a   Kratzke, R A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Apoptosis; Fas ligand; Myelodysplastic syndromes; Prognostic factors

Indexed keywords

FAS LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; BONE MARROW; BONE MARROW CELL; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOPENIA; ERYTHROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; METAPHASE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; STEM CELL; SURVIVAL RATE;

EID: 0032945317     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401233     Document Type: Article

References (47)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. The French-American-British Co-operative Group: proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
2. Weisdorf DJ, Oken MM, Johnson GJ, Rydell RE. Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia. Br J Haematol 1983; 55: 691-700.
3. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425-433.
4. Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med 1991; 90: 338-344.
5. Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk Lymphoma 1990; 2: 415-418.
6. Raza A, Gezer S, Mundle S, Gao X, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1985; 86: 268-276.
7. Hatake K, Tomizuka H, Ikeda M, Tsunoda JI, Hoshino Y, Ohtsuki T, Kasahara T, Yonehara S, Miura Y. The presence of apoptosis in refractory anemia of myelodysplasia. In: Abraham NG (ed). Molecular Biology of Haematopoiesis, vol 3. Intercept: Andover, UK 1994, pp 127.
8. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11: 839-845.
9. Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol 1996; 95: 368-371.
10. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88: 4275-4287.
11. Anzai N, Kawabata H, Hishita T, Ueda Y, Yoshida Y. Apoptosis in MDS. J J Clin Hematol 1996; 37: 536-541.
12. Hellström-Lindberg E, Kanter-Lewensohn L, Öst A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leukemia Res 1997; 21: 415-425.
13. Yoshida Y, Anzai N, Kawabata H. Apoptosis in myelodysplasia: a paradox or paradigm? Leukemia Res 1995; 19: 887-891.
14. Bogdanovic AD, Trpinac DP, Iankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndromes: morphological and ultrastructural assessment. Leukemia 1997; 11: 656-659.
15. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998; 12: 486-492.
16. Mundle SD, Gao XZ, Khan S, Gregory SA, Preisler HD. Two in situ labeling techniques reveal different patterns of DNA fragmentation during spontaneous apoptosis in vivo and induced apoptosis in vitro. Anticancer Res 1995; 15: 1895-1904.
17. Nagata S, Golstein P. The fas death factor. Science 1995; 267: 1449-1456.
18. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y. Functional expression of fas antigen (CD95)on hematopoietic progenitor cells. Blood 1995; 86: 883-889.
19. + human marrow cells is induced by interferon-γ and tumor necrosis factor-α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183-3190.
20. + T cells and monocytes. Cell Immunol 1995; 163: 303-308.
21. Koury MJ. Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol 1992; 20: 391-394.
22. Mori T, Ando K, Tanaka K, Ikeda Y, Koga Y. Fas-mediated apoptosis of the hematopoietic progenitor cells in mice infected with murine cytomegalovirus. Blood 1997; 89: 3565-3573.
23. Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguchi N. Differential expression of bcl-2 and susceptibility to anti-fas-mediated cell death in peripheral blood lymphocytes, monocytes and neutrophils. Blood 1994; 84: 1201-1208.
24. Barcena A, Park SW, Banapour B, Muench MO, Mechetner E. Expression of fas/CD95 and bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood 1996; 88: 2013-2025.
25. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl2 prolein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88: 6961-6965.
26. Dai C-H, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon-γ to produce erythroid cell apoptosis. Blood 1998; 91: 1235-1242.
27. + cells of patients with aplastic anaemia. Br J Haematol 1995; 91: 245-252.
28. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, Gezer S, Parcharidou A, Venugopal P, Shah R, Hernandez B, Klein M. Alston D, Robin E, Dominquez C, Raza A. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leukemia Res 1996; 20: 891-900.
29. Anastasi J, Feng J, LeBeau MM, Larson RA, Rowley JD, Vardiman JW. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy and clonal expansion. Blood 1993; 81: 1580-1585.
30. Culligan DJ, Bowen DT, May A, White D, Padua RA, Burnett AK. Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression. Br J Haematol 1995; 89: 675-677.
31. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA. Human lung carcinomas express fas ligand. Cancer Res 1997; 57: 1007-1012.
32. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The fas counterattack - fas-mediated T cell killing by colon cancer cells expressing fas ligand. J Exp Med 1996; 184: 1075-1082.
33. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1997; 2: 1361-1366.
34. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC, Tschopp J. Melanoma cell expression of Fas (APO-1/CD95) ligand - implications for tumor immune escape. Science 1996; 274: 1363-1366.
35. Villunger A, Egle A, Marschitz I, Kos M, Bock G, Ludwig H, Geley S, Kofler R, Greil R. Constitutive expression of fas (APO-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90: 12-20.
36. Cascino I, Papoff G, de Maria R, Testi R, Ruberti G. Fas/APO-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 1996; 156: 13-17.
37. Gersuk GM, Lee JW, Beckham CA, Anderson J, Deeg HJ. Fas (CD95) receptor and fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 1996; 88: 1122-1123 (letter).
38. Gupta P, McCarthy JB, Verfaillie CM. Stromal fibroblast heparan sulfate is required for cytokine-mediated ex vivo maintenance of human long-term culture-initiating cells. Blood 1996; 87: 3229-3236.
39. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T cell hybridomas. Nature 1995; 373: 441-444.
40. Verfaillie C, McGlave P. Leukemia inhibitory factor/human interleukin for DA cells: a growth factor that stimulates the in vitro development of multipotential human hematopoietic progenitors. Blood 1991; 77: 263-270.
41. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
42. Varela BL, Chuang C, Woll JE, Bennett JM. Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system. Hematol Oncol 1985; 3: 55-63.
43. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo syngery. Blood 1996; 87: 4076-4081.
44. Raza A, Gezer S, Gregory SA, Venugopal P, Kaizer H, Dong LM, Span L, Hines C, Thomas R, Alvi S, Mundle SD, Shetty V, Borok R, Loew J, Reza S, Robin EL, Rifkin SD, Alston D, Hernandez BM, Shah R, Hsu W-T, Dar S, Preisler HD. Anti-cytokine therapy produces responses in patients with myelodysplastic syndromes (MDS). Blood 1996; 88: (Suppl. 1): 580a (Abstr).
45. Mundle SD, Venugopal P, Cartlidge JD, Pandav DV, Broady-Robinson L, Gezer S, Rohin EL, Rifkin S, Klein M, Alston DE, Hernandez B, Rosi D, Alvi S, Shetty V, Gregory SA, Raza A. Indication of an involvement of interleukin-1 β converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 1996; 88: 2640-2647.
46. Xerri L, Devilard E, Hassoun J, Haddad P, Birg F. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 1997; 11: 1868-1877.
47. Perzova R, Loughran TP Jr. Constitutive expression of Fas ligand in large granular lymphocyte leukemia. Br J Haematol 1997; 97: 123-126.